This new syndrome of paraganglioma, somatostatinoma, and polycythemia provides a unique opportunity to study the impact of hypoxia signaling, specifically gain-of-function of HIF2α, on tumorigenesis. The gene discussed is EPAS1; the disease is somatostatinoma.